Clinical trials
Phase 2 Prostatic Neoplasms trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
32 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 5 |
| Active, not recruiting | 4 |
| Terminated | 4 |
| Unknown status | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 3 |
| Bristol-Myers Squibb | 3 |
| Novartis Pharmaceuticals | 3 |
| St Vincent's Hospital, Sydney | 3 |
| Astellas Pharma Global Development, Inc. | 1 |
| Astellas Pharma Inc | 1 |
| AstraZeneca | 1 |
| Bayer | 1 |
| Cancer Therapeutics Research Group | 1 |
| Daiichi Sankyo | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Prostatic Neoplasms | 32 |
| Breast Neoplasms | 3 |
| Melanoma | 3 |
| Neoplasm Metastasis | 3 |
| Pancreatic Neoplasms | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Endometrial Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
| Head and Neck Neoplasms | 2 |
| Kidney Neoplasms | 2 |
Trials
Showing 1 to 25 of 32. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.